DNMT3B and hepatocellular carcinoma: Cellular study indicated that DNMT3B expression was increased in sorafenib‐resistant HCC cells, and DNMT3B‐specific inhibitor nanaomycin A dose‐dependently increased sorafenib sensitivity [34].